CA2865774A1 - Psma as a biomarker for androgen activity in prostate cancer - Google Patents

Psma as a biomarker for androgen activity in prostate cancer Download PDF

Info

Publication number
CA2865774A1
CA2865774A1 CA2865774A CA2865774A CA2865774A1 CA 2865774 A1 CA2865774 A1 CA 2865774A1 CA 2865774 A CA2865774 A CA 2865774A CA 2865774 A CA2865774 A CA 2865774A CA 2865774 A1 CA2865774 A1 CA 2865774A1
Authority
CA
Canada
Prior art keywords
psma
imaging
patient
prostate cancer
measurement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865774A
Other languages
English (en)
French (fr)
Inventor
Neil H. Bander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CA2865774A1 publication Critical patent/CA2865774A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2865774A 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer Abandoned CA2865774A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604039P 2012-02-28 2012-02-28
US61/604,039 2012-02-28
PCT/US2013/000051 WO2013130177A1 (en) 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer

Publications (1)

Publication Number Publication Date
CA2865774A1 true CA2865774A1 (en) 2013-09-06

Family

ID=49083148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865774A Abandoned CA2865774A1 (en) 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer

Country Status (6)

Country Link
US (1) US20130315830A1 (enExample)
EP (1) EP2819704A4 (enExample)
JP (1) JP2015508903A (enExample)
CA (1) CA2865774A1 (enExample)
HK (1) HK1202256A1 (enExample)
WO (1) WO2013130177A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271462A1 (en) 2013-03-13 2014-09-18 Imaginab, Inc. Antigen binding constructs to cd8
JP7026613B2 (ja) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
JP7284707B2 (ja) 2017-04-07 2023-05-31 ジュノー セラピューティクス インコーポレイテッド 前立腺特異的膜抗原（ｐｓｍａ）またはその改変型を発現する操作された細胞および関連方法
US20220001043A1 (en) * 2018-09-28 2022-01-06 Imaginab, Inc. Cd8 imaging constructs and methods of use thereof
US20240011996A1 (en) * 2020-11-24 2024-01-11 Korea Institute Of Science And Technology Biomarkers for diagnosing prostate cancer, combination thereof, and use thereof
EP4267969A4 (en) * 2020-12-22 2025-02-12 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF PROSTATE CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007037A (es) * 2001-02-07 2003-11-18 Beth Israel Hospital Ligandos del antigeno de membrana especifico de prostata (amep) y usos relacionados del mismo.
US20090130108A1 (en) * 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
JP5951929B2 (ja) * 2007-10-03 2016-07-13 コーネル ユニヴァーシティー Ｐｓｍａ抗体を用いる増殖性障害の治療
US20100047166A1 (en) * 2008-08-20 2010-02-25 Kanner Steven B Antibodies and related molecules that bind to 58p1d12 proteins
US10517969B2 (en) * 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP3222617B1 (en) * 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
EP2419507A1 (en) * 2009-04-14 2012-02-22 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
JP6501524B2 (ja) * 2012-02-24 2019-04-17 コーネル ユニヴァーシティー Ｐｓｍａ上昇により致死性前立腺癌が同定される

Also Published As

Publication number Publication date
EP2819704A4 (en) 2015-10-21
JP2015508903A (ja) 2015-03-23
US20130315830A1 (en) 2013-11-28
WO2013130177A1 (en) 2013-09-06
EP2819704A1 (en) 2015-01-07
HK1202256A1 (en) 2015-09-25

Similar Documents

Publication Publication Date Title
Chen et al. TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency
Tiwari et al. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer
US20130315830A1 (en) PSMA as a BioMarker for Androgen Activity in Prostate Cancer
Surowiak et al. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome
Blouw et al. The invadopodia scaffold protein Tks5 is required for the growth of human breast cancer cells in vitro and in vivo
US20250230259A1 (en) Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
Nickkho-Amiry et al. Peroxisome proliferator–activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma
Makris et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study
Long et al. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
Wang-Rodriguez et al. Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status
AU2016270686A1 (en) Quantifying Her2 protein for optimal cancer therapy
Wang et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts
Wu et al. ATXN3 promotes prostate cancer progression by stabilizing YAP
Liu et al. Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression
Feng et al. Deubiquitinase USP10 promotes osteosarcoma autophagy and progression through regulating GSK3β-ULK1 axis
Ames et al. Huntingtin-interacting protein 1: a Merkel cell carcinoma marker that interacts with c-Kit
Ke et al. Mechanical signal modulates prostate cancer immune escape by USP8-mediated ubiquitination-dependent degradation of PD-L1 and MHC-1
Lang et al. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy
Gaber et al. Obesity increases DNA damage in the breast epithelium
Chocarro-Calvo et al. Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression
Diao et al. MEK5 overexpression is associated with the occurrence and development of colorectal cancer
US7718393B2 (en) Method for determining the efficacy of an anthracycline anticancer agent
WO2017172734A1 (en) Treating cancer metastasis
Huang et al. Clinicopathological and cellular signature of PAK1 in human bladder cancer
Halin Bergström et al. High‐grade tumours promote growth of other less‐malignant tumours in the same prostate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180226

FZDE Discontinued

Effective date: 20210831